No Detail Found!

Effect of methotrexate on clinical course of COVID-19 in patients with autoimmune rheumatic diseases

Author(s)
Shahida Perveen Department of Rheumatology, Foundation University Medical College, Fauji Foundation Hospital,Rawalpindi,Pakistan
Haris Gul Department of Rheumatology, Foundation University Medical College, Fauji Foundation Hospital,Rawalpindi,Pakistan
Saba Samreen Department of Rheumatology, Foundation University Medical College, Fauji Foundation Hospital,Rawalpindi,Pakistan
Babur Salim Department of Rheumatology, Foundation University Medical College, Fauji Foundation Hospital,Rawalpindi,Pakistan
Abstract
Objective: To determine the effect of methotrexate (MTX) on clinical course of COVID-19 in autoimmune rheumatic disorders (AIRD). Methodology: This observational cohort study was carried out at Fauji Foundation Hospital, Rawalpindi, Pakistan. We recruited 100 patients with AIRD having COVID-19. Data related to demographics, AIRD (diagnosis, treatment, activity) and COVID-19 {symptoms, duration, complications, and outcome (Mortality, invasive ventilation, hospitalization, and ICU admission} were recorded. Patients were divided into 2 groups: group 1 using MTX and group 2 not using MTX. These were compared using chi-square, student's t-test and logistic regression. Results: MTX was used by 48% of patients. Group 1 patients were older than group 2 (49.3±13.65 vs 41.69±12.84; t -3.07, p=0.003). Dyspnea (56% vs 36%) and altered taste (27% vs 10%) were significantly higher in group1 (LR 3.9, 5.16 and p=0.048 and 0.02, respectively). Mortality (LR 1.33, p=0.25), hospitalization (LR 0.24, p=0.63), ICU admission (LR 2.06, p=0.15) and ventilation (LR 0.8, p=0.78) were same in both groups. Steroid users in group 1 had higher mortality (20% vs none, LR 6.15, p=0.013) than group 2 (32% vs 11%, LR 3.38, p=0.06). Higher AIRD activity was associated with higher mortality (LR 13.53, p=0.004) and ventilation requirements (LR 9.96, p=0.019) only in group 2. Conclusion: Methotrexate may favourably alter the course of COVID-19 in patients with AIRD. But its effect may be modified by other factors like steroid use and AIRD activity.
Publication Details
Page(s) 1-6
DOI DOI not available
Published Journal: Rawal Medical Journal, Volume: 49, Issue: 4, Year: 2024

Request the full text from PASTIC

Keywords
Mortality, Rheumatoid arthritis, Steroid, COVID 19, Methotrexate, Ventilation.
References
Coronavirus (COVID19) Dashboard . .. 2023 [cited 2023 Dec, 28 : .
. .. 2023 [cited 2023 Jan, 12 : .
Global . .. net/covid19/global-covid-19-case-fatality-rates/., 22 : .
Pablos JL,Abasolo L,Alvaro-Gracia JM,Blanco FJ,Blanco R,Castrejón I .2020 .Prevalence of hospital PCRconfirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Ann Rheum Dis, 79 : 1170.
Santos CS,Morales CM,Álvarez ED,Castro CÁ,Robles AL,Sandoval TP .2020 .Determinants of COVID-19 disease severity in patients with underlying rheumatic disease. Clin Rheumatol, 39 : 2789-96.
Gianfrancesco M,Hyrich KL,Al-Adely S,Carmona L,Danila MI,Gossec L .2020 .Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis, 79 : 859-66.
Mikuls TR,Johnson SR,Fraenkel L,Arasaratnam RJ,Baden LR,Bermas BL .2021 .American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID19 Pandemic: Version 3. Arth Rheumatol, 73 : 1-12.
Caruso A,Caccuri F,Bugatti A,Zani A,Vanoni M,Bonfanti P .2021 .Methotrexate inhibits SARS-CoV-2 virus replication “in vitro. ” J Med Virol, 93 : 1780-5.
Schälter F,Dürholz K,Bucci L,Burmester G,Caporali R,Figuereido C .2021 .Does methotrexate influence COVID19 infection? Case series and mechanistic data. Arth Res Ther, 23 : 166-70.
Coronavirus Disease 2019,- Disease 2019 .2020 .. (COVID-19) | 2020 Interim Case Definition, Approved April 5, : .
Yousaf A,Gayam S,Feldman S,Zinn Z,Kolodney M. .2021 .Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors or methotrexate: A multicenter research network study. J Am Acad Dermatol, 84 : 70-5.
Veenstra J,Buechler CR,Robinson G,Chapman S,Adelman M,Tisack A .2020 .Antecedent immunosuppressive therapy for immune-mediated inflammatory diseases in the setting of a COVID-19 outbreak. J Am Acad Dermatol, 83 : 1696-703.
Opdam MAA,Benoy S,Verhoef LM,Van Bijnen S,Lamers-Karnebeek F,Traksel RAM .2022 .Identification of Risk Factors for COVID-19 Hospitalization in Patients with Anti-Rheumatic Drugs: Results from a Multicenter Nested Case Control Study. Clin Pharmacol Ther, 111 : 1061-5.
Topless RK,Green R,Morgan SL,Robinson PC,Merriman TR,Gaffo AL .2022 .Folic acid, and methotrexate use and their association with COVID-19 diagnosis and mortality: an analysis from the UK BIOBANK. , 12 : e062945.
Haberman RH,Castillo R,Chen A,Yan D,Ramirez D,Sekar V .2020 .-19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes. Arth Rheumatol (Hoboken. , 72 : 1981-9.
Thomas DC,Chablani D,Parekh S,Pichammal RC,Shanmugasundaram K,Pitchumani PK .2022 .Dysgeusia: A review in the context of COVID-19. J Am Dent Assoc, 153 : 251-64.
Van Kessel S,Olde Hartman T,Lucassen P .2022 .Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. Fam Pract, 39 : 159-67.
Strangfeld A,Schäfer M,Gianfrancesco MA,LawsonTovey S,Liew JW,Ljung L .2021 .Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis, 80 : 930-42.
Kihara M,Sugihara T,Asano J,Sato M,Kaneko H,Muraoka S .2022 .Clinical characteristics of COVID-19 patients with underlying rheumatic diseases in Japan: data from a multicenter observational study using the COVID19 Global Rheumatology Alliance physician-reported registry. Clin Rheumatol, 41 : 3661-73.
Alpizar-Rodriguez D,Irazoque-Palazuelos F,RodriguezReyne TS,Zamora E,Friedmann DXX,Ortiz AC .2021 .POS1242 Factors associated with mortality in patients with rheumatic diseases and COVID-19 in Mexico. Ann Rheum Dis, 80 : 904-904.
Florence A,Nassim AA,Jean-David A,Yannick A,Blanca AB,Zahir A .2021 .Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: Data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis, 80 : 527-38.
Esatoglu SN,Tascilar K,Babaoğlu H,Bes C,Yurttas B,Akar S .2021 .-19 Among Patients with Inflammatory Rheumatic Diseases. Front Immunol, 12 : 1226.
Kridin K,Schonmann Y,Tzur Bitan D,Damiani G,Peretz A,Weinstein O .2021 .COVID19)-Associated Hospitalization and Mortality in Patients with Psoriasis: A Population-Based Study. Am J Clin Dermatol, 22 : 709-18.
Gracia JMÁ,Sanchez-Piedra C,Manero J,Ruiz-Lucea ME,López-Vives L,Bohorquez C .2021 .Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study. RMD open, 7 : e001925.
0

Citations

0

Downloads

36

Views